Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates

Completed · Not applicable

Conditions studied: Heart Failure

In brief

The purpose of this study is to demonstrate that cardiac resynchronization therapy (CRT) responder rate can be improved by 3-dimensional (3D) echo-guided left ventricular (LV) lead placement compared to traditional LV lead placement.

Key facts

Study ID

NCT01278030

Run by

Abbott Medical Devices

People needed

78

Starts

2010-08-01

Last updated by the study team

2019-02-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will be implanted with an FDA approved St. Jude Medical CRT-D device (i.e. PROMOTE® or newer devices with similar functionality)
• Patients will have an approved indication per American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for implantation of a CRT-D
• Patients will receive a new implant or an upgrade from an existing pacemaker or Implantable Cardiovertor Defibrillator with no prior Left Ventricular lead placement
• Patients must be in sinus rhythm at the time of enrollment visit and baseline measurements

You may not qualify if…

• Persistent or permanent atrial fibrillation
• Heart transplantation
• Recent myocardial infarction (< 90 days)
• Contra-indication to contrast agent
• Are less than 18 years of age
• Are pregnant
• Are currently participating in a clinical investigation that includes an active treatment arm
• Have a life expectancy of less than 6 months

Where it is running

• The Heart Group — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.